OSI DPP-IV Inhibitor Is A “Sensible Approach” To Diabetes Dosing, Firm Says
Executive Summary
The meal-related dosing schedule of OSI Pharmaceuticals' type 2 diabetes candidate PSN9301 could lead to better patient compliance, the company said
You may also be interested in...
Novartis Takes Aim: Galvus Promotions To Target Other Classes, Not Januvia
Novartis' strategy for launching its dipeptidyl peptidase IV inhibitor Galvus will be to position the antidiabetic as an option against other existing therapeutic classes, not head-to-head against Merck's DPP-IV Januvia
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011